Beta BionicsvsThermo Fisher Scientific

BBNX and TMO stock compared: price, dividend, valuation and results, from SEC filings.

BBNX

Beta Bionics, Inc.

$15.21

Value $827M

-7.37%
BBNX's page

TMO

Thermo Fisher Scientific Inc

$691.33

Value $257B

-1.27%
TMO's page

Beta Bionics (BBNX) has a market value of $827M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, BBNX moved -44.0% and TMO +19.9%. Dividend yield: BBNX none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BBNX$827M

    TMO$257B

    TMO is 311 times BBNX

  • Revenue, 12 months

    BBNX$127M

    TMO$47.4B

    TMO is 372 times BBNX

  • Net income, 12 months

    BBNX-$83M

    TMO$7.1B

  • Operating margin

    BBNX-72.8%

    TMO17.9%

    90.6 points apart

  • ROIC

    BBNX-24.2%

    TMO8.2%

    32.4 points apart

  • P/E

    BBNX–

    TMO36.3

  • Dividend yield

    BBNX0.0%

    TMO0.3%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BBNX-44.0%

TMO+19.9%

5075100125DecFebAprJunAugOct
Returns by period
PeriodBBNXWith dividendsTMOWith dividends
1 year since November 14, 2025-44.0%Price -44.0%+19.9%Price +19.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BBNXBeta BionicsTMOThermo Fisher Scientific

Valuation

BBNXTMO
Valuation
Price$15.21$691.33
Market value$827M$257B
Enterprise value (EV)$587M$292B
P/E–36.3
P/E, 5-year median–32.7
P/B2.14.7
EV/EBIT–34.5
Free cash flow yield–3.0%

Results and growth

BBNXTMO
Results and growth
Revenue, 12 months$127M$47.4B
Net income, 12 months-$83M$7.1B
Free cash flow, 12 months-$66M$7.6B
Earnings per share, 12 months-$1.83$18.96
Revenue growth, year on year53.9%3.9%
Revenue growth a year, past+189.1%over 2 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

BBNXTMO
Margins and returns on capital
Gross margin58.6%–
Operating margin-72.8%17.9%
Net margin-65.3%14.9%
ROIC-24.2%8.2%
ROE-27.5%13.4%

Balance sheet

BBNXTMO
Balance sheet
Cash$240M$6.1B
Total debt$6.2M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

BBNXTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BBNX or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Beta Bionics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 310.6 times Beta Bionics ($827M), at today's prices.

How did BBNX and TMO stock do over the last 1 years?

Since November 14, 2025, BBNX's price moved -44.0% and TMO's +19.5%. With dividends: BBNX -44.0% (-44.0% a year), TMO +19.9% (+19.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, BBNX or TMO?

The dividend yield at today's price is none for Beta Bionics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Beta Bionics or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -65.3% for Beta Bionics and 14.9% for Thermo Fisher Scientific, and the operating margin -72.8% and 17.9%. Revenue was $127M and $47.4B.

Which is the better investment, Beta Bionics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.